Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histo
| Condition(s) | Thymic Epithelial Tumor, Thymic Carcinoma, Thymoma, Thymoma and Thymic Carcinoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of |
| Who can participate | Inclusion Criteria: Participants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically: * Thymoma A * Thymoma AB * Thymoma B1 * Thymoma B2 * Thymoma B3 * Thymic Carcinoma Inclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model. Recurrence Criteria: Participants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase. |
| Sex | All |
| Lead sponsor | Erasmus Medical Center |
| Locations | Rotterdam, South Holland, Netherlands |
| Start date | 2023-08-01 |
| NCT ID | NCT06301945 |
| Official listing | https://clinicaltrials.gov/study/NCT06301945 |